april 11 2012... maybe CPRX investors should do the same... ARNA investors filled a lawsuit against Adam Feuerstein on 4/11/2012 in the next monthe the shareprice of ARNA shoot up from 2 to 11 dollar.
How can you do good DD on 300 articles in 10months? 1 article a day... what does this guy do? Google internet short or buy a stock andd then write an article... few days later sell or cover. Come on ADAM F is a 5th rang journalist.
From the Catalyst Phar website under Firedapse Questions and anwsers...
there other companies developing amifampridine (3,4-DAP) for the treatment of LEMS?
Catalyst believes that Firdapse™ is the only version of amifampridine phosphate (3,4-DAP) in Phase III trials for LEMS. However, Catalyst is aware that another pharmaceutical company is conducting a Phase II clinical trial in the U.S. for its version of amifampridine (3,4-DAP) for the treatment of LEMS.
true... nothing has changed... only the PPS lol. CPRX will recover. CEO gave a good signal yesterday by buying shares. He is holding 3.5mil shares. Last offering e few weeks ago was at 1.74... This is a no brainer at this point. A lot of investors got scared when they saw the PPS drop and melt away all of there profits. CPRX will turn around fast and furious imo.
Patrick J. McEnany, Catalyst's Chairman and CEO, stated: "We are pleased to have completed this financing, which we believe, along with the proceeds from recent warrant exercises, gives us the capital necessary to fund development of Firdapse™ and allows us to begin new clinical studies for CPP-115." Mr. McEnany continued: "We are also excited that several high quality fundamental life science investors, including New Leaf Venture Partners, participated in our offering."
Cprx did an offering a few week ago at 1,74 dollar... Yep those big investors at 1,74 did no DD. You just made yourself fool of the day.
...The panic selling that occurred with Catalyst Pharmaceutical due to Adam Feuerstein's investigative article on Friday was overdone, and the fact remains that nothing has fundamentally changed for the company. The drug Firdapse is still expected to release positive results next year, gain FDA approval the following year, and commence sales by 2016, reaching peak annual sales of up to $300 million. Include the fact that the true value behind this company lies behind Rick Silverman's development of CPP-115, which wasn't even mentioned in Feuerstein's article, and you have a stock that is sure to rebound from this sharp sell-off.
Aegis Capital is boosting its price target of Catalyst Pharmaceutical Partners (Nasdaq: CPRX) from $4 to $5.50, while maintaining a Buy rating on the company.
Analyst Ram Selvaraju raised his expectations on Firdapse pricing, saying, „as we currently believe that this agent is likely to be the sole approved therapy for Lambert-Eaton myasthenic syndrome (LEMS) in the U.S.” The analyst initially modeled a price of $30,000 annually for Firdapse, but not thinks that price could be around $70,000 per year and said, „this raises our riskadjusted
Net Present Value (rNPV) for the product from $120mm to $230mm. Immediately after a recent capital raise, Catalyst had $27mm in pro forma cash - sufficient capital to sustain operations through 2014 and filing of a New Drug Application (NDA) for Firdapse.”
On competition in the segment, Selvaraju comments that recent blog posts have mentioned a company named Jacobus Pharmaceutical Co., Inc., „which is conducting a Phase 2 trial of 3,4-diaminopyridine, the same active pharmaceutical ingredient (API) as that found in Firdapse. We have known about the existence of Jacobus since Huxley Pharmaceuticals originally acquired the rights to 3,4-diaminopyridine in the U.S. from EUSA Pharma. Jacobus - despite stating that it has been supplying 3,4-diaminopyridine to LEMS patients in the U.S. for many years - has never attempted to secure FDA approval for its drug and currently has neither a cGMPcompliant manufacturing facility nor a formal pivotal trial protocol in place.”
Should Catalyst Pharma be able to obtain FDA Orphan Drug status for Firdapse in LEMS, no other company would be able to sell 3,4-diaminopyridine in the U.S. until expiration of the designation.
For an analyst ratings summary and ratings history on Catalyst Pharma click here. For more ratings news on Catalyst Pharmaceutical Partners click here.
Shares of Catalyst Pharma closed at $1.90 last Friday, with a 52 week range of $0.37 - $3.65.
Friday AH ask was at 1.75 now 1.9... looks like recovering comming this week. I can't believe a stock can drop 30% just beceause 1 man is telling lies on internet. They should sue AF.
Fridays article just doesn't matter... This week was just a little correction after great gains the article just scared some extra and uninformd investors. CPRX will recover in the next weeks and find new hights. Traget going higher and higher, last week under 4 dollar weekend 4,16 today 4,33... By the end of the year Cprx will trade over 5 dollar. Glta